• Home
  • Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.

Author List
Oh DY, Algazi A, Capdevila J, Longo F, Miller W, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L
Publication
Cancer
Publication ID (Profile URL)
https://researcherprofiles.org/profile/368190141
Publication Year
2023
PubMed ID
36748723
Publication Title
Oh DY, Algazi A, Capdevila J, Longo F, Miller W, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer. 2023 04 15; 129(8):1195-1204.